<DOC>
	<DOCNO>NCT01360125</DOCNO>
	<brief_summary>RATIONALE : Studying sample bone marrow blood patient cancer laboratory may help doctor predict well patient respond treatment . PURPOSE : This research study study biomarkers sample patient newly diagnose acute myeloid leukemia treat cytarabine-based chemotherapy .</brief_summary>
	<brief_title>S0106A , Biomarkers Samples From Patients With Newly Diagnosed Acute Myeloid Leukemia Treated With Cytarabine-Based Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : - Training test multiparameter flow cytometry-based cell signal signature ( FC classifier 1 ) associate vivo primary chemoresistance ( i.e. , non-complete response [ NR ] ) standard induction therapy adult patient ≤ 60 year old newly diagnose non-M3 acute myeloid leukemia ( AML ) . - Training test multiparameter flow cytometry-based cell signal signature ( FC classifier 2 ) associate complete continuous response 1 year ( CCR1 ) adult patient ≤ 60 year old newly diagnose non-M3 AML treat cytarabine-based induction chemotherapy . - Identification signal signature ( ) associate secondary chemoresistance ( i.e. , disease relapse ) adult patient ≤ 60 year age longitudinally pair peripheral blood mononuclear cell ( PBMC ) bone marrow mononuclear cell ( BMMC ) sample diagnosis time first relapse . ( Exploratory ) OUTLINE : Cryopreserved sample incubate cytokine ( e.g. , interleukin ) , growth factor ( e.g. , sargramostim [ GM-CSF ] filgrastim [ G-CSF ] ) , chemotherapeutic agent ( e.g. , cytarabine , etoposide phosphate ) , modulators . Cells fix , permeabilized , stained antibody recognize extracellular marker conjunction intracellular activation-state specific epitope designate signal molecule . Subsequently , cell analyze multiparametric phospho-flow cytometry random manner ( without knowledge clinical variable outcomes ) train test set . Results compare individual patient clinical outcome .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Newly diagnose nonM3 acute myeloid leukemia ( AML ) Pretreatment relapse and/or refractory cryopreserved bone marrow mononuclear cell ( BMMCs ) peripheral blood mononuclear cell ( PBMCs ) available Have 2+ vial pretreatment marrow cell and/or 2+ vial pretreatment PBMCs Southwestern Oncology Group ( SWOG ) AML/Myelodysplastic Syndrome ( MDS ) Repository Usable sample must contain approximately 1.6 ×10^6 cluster differentiation antigen 45+ ( CD45+ ) cell post thaw . Eligible evaluable patient participate SWOGS0106 study PATIENT CHARACTERISTICS : Did refuse consent use specimens PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute erythroid leukemia ( M6 )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia del ( 5q )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
</DOC>